Department of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Center, Dr. HL Trivedi Institute of Transplantation Sciences (IKDRC-ITS), Ahmedabad, India.
Ren Fail. 2013;35(4):504-8. doi: 10.3109/0886022X.2013.773914. Epub 2013 Mar 11.
Kidney Paired Donation (KPD) is a rapidly growing modality for facilitating living related donor kidney transplantation (LRDKTx) for patients who are incompatible with their healthy, willing, and living donors. Data scarcity on the outcome of KPD versus LRDKTx prompted us to review our experience.
This was a single-center study of 224 patients on regular follow-up, who underwent LRDRTx from January 2010 to June 2012 at our institute. The aim of this study was to compare short-term graft survival, patient survival and rejection rates of KPD (group 1, n = 34) with those of LRDKTx (group 2, n = 190). All the recipients received triple immunosuppression and thymoglobulin induction in KPD group. Kaplan-Meier curves were used for survival analysis. In group 1, mean recipient age was 35.5 ± 13.2 years, 29 were men and mean donor age was 44.4 ± 8.17 years, 10 were men. In group 2, mean recipient age was 29.1 ± 10 years, 155 were men and mean donor age was 47.5 ± 9.69 years, 74 were men. Mean human leukocyte antigen (HLA) matching in group 1 and 2 was 1 versus 3.2 (p < 0.05).
One- and two-year patient survival showed no significant difference between the two groups (97.1%, 97.1% vs. 96.2%, 94.8%, respectively, p = 0.81). Death-censored graft survival also showed no significant difference between the two groups (97.1%, 97.1%, vs. 97.6%, 97.6%, p = 0.73). Acute rejection incidence was also similar (8.7% vs. 9.9%, p > 0.62).
Our study showed similar graft survival, patient survival and rejection rates of KPD versus LRDKTx over 2 years post-transplantation, encouraging the use of this approach for national KPD program.
肾配对捐赠(KPD)是一种快速发展的模式,可促进不相容的健康、愿意且存活的供体与受者进行活体相关供肾移植(LRDKTx)。由于缺乏 KPD 与 LRDKTx 结局的数据,我们对我们的经验进行了回顾。
这是一项单中心研究,纳入了 224 例在我院接受 LRDKTx 的患者,这些患者在 2010 年 1 月至 2012 年 6 月期间接受了随访。本研究的目的是比较 KPD(第 1 组,n=34)与 LRDKTx(第 2 组,n=190)的短期移植物存活率、患者存活率和排斥率。KPD 组所有受者均接受三联免疫抑制和胸腺球蛋白诱导。采用 Kaplan-Meier 曲线进行生存分析。第 1 组的受者年龄为 35.5±13.2 岁,其中 29 例为男性,供者年龄为 44.4±8.17 岁,其中 10 例为男性。第 2 组的受者年龄为 29.1±10 岁,其中 155 例为男性,供者年龄为 47.5±9.69 岁,其中 74 例为男性。第 1 组和第 2 组的平均人类白细胞抗原(HLA)匹配数分别为 1 对 3.2(p<0.05)。
两组患者的 1 年和 2 年存活率均无显著差异(分别为 97.1%、97.1% vs. 96.2%、94.8%,p=0.81)。死亡风险调整移植物存活率也无显著差异(分别为 97.1%、97.1% vs. 97.6%、97.6%,p=0.73)。急性排斥反应发生率也相似(8.7% vs. 9.9%,p>0.62)。
我们的研究表明,KPD 与 LRDKTx 在移植后 2 年内具有相似的移植物存活率、患者存活率和排斥率,这鼓励了将这种方法用于国家 KPD 计划。